Search - tctmd.com

Displaying 21 - 40 of 74

Sort: Relevancy | Date

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Conference News AHA 2022

Mindfulness Could Combat Uncontrolled Hypertension: MB-BP

Yael L. Maxwell

November 14, 2022

News Conference News AHA 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

Caitlin E. Cox

November 11, 2022

News Conference News AHA 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

Shelley Wood

November 10, 2022

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

News Conference News AHA 2022

China Rural Intervention Still Reaping BP Control Wins at 3 Years

L.A. McKeown

November 09, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

Caitlin E. Cox

November 08, 2022

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

Todd Neale

November 05, 2022

News Conference News AHA 2022

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

L.A. McKeown

November 01, 2022

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

News Conference News AHA 2021

Dietary Patterns, Social Pressures: AHA Offers New Nutrition Advice

Caitlin E. Cox

November 19, 2021

News Conference News AHA 2021

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

L.A. McKeown

November 18, 2021

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

Advertisement

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

What’s Going to Be Hot at AHA 2023

Mindfulness Could Combat Uncontrolled Hypertension: MB-BP

Sizeable Minority of Pregnant Women Have CVD, US Data Show

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

China Rural Intervention Still Reaping BP Control Wins at 3 Years

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Dietary Patterns, Social Pressures: AHA Offers New Nutrition Advice

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content